Asthma Population Management: Identifying Persistent Asthma, Defining High Risk Asthma, and Measuring Quality of Asthma Care
|
|
|
- Sydney Hart
- 5 years ago
- Views:
Transcription
1 Asthma Population Management: Identifying Persistent Asthma, Defining High Risk Asthma, and Measuring Quality of Asthma Care Michael Schatz, MD, MS Allergy Department Kaiser Permanente, San Diego, CA
2 Constructs to be Measured Severity (Persistent Asthma) Control Impairment Exacerbations Quality of Care
3 Types of Administrative Data Used Encounter diagnosis of asthma Hospital Emergency Department Outpatient Pharmacy data Short-acting beta agonist canisters Oral corticosteroid dispensings Controller units and percent of days covered
4 Outline of Presentation Assessment of Severity Persistent asthma (HEDIS) Assessment of Impairment Short-acting β-agonist canister dispensings Assessment of Risk (Exacerbations) Prior exacerbations Short-acting β-agonist canister dispensings Assessment of Quality Care (HEDIS) Any controller measure Medication ratio measure Adherence measure
5 Outline of Presentation Assessment of Severity Persistent asthma (HEDIS) Assessment of Impairment Short-acting β-agonist canister dispensings Assessment of Risk (Exacerbations) Prior exacerbations Short-acting β-agonist canister dispensings Assessment of Quality Care (HEDIS) Any controller measure Medication ratio measure Adherence measure
6 Question Which of the following is true regarding the HEDIS definition for persistent asthma? A. It appears to have low specificity for persistent asthma based on patient-reported information B. It includes pulmonary function measures, which increases its specificity C. A two year definition increases its specificity D. It does not include exacerbations
7 HEDIS Persistent Asthma HEDIS definition of persistent asthma > 4 or more asthma medication dispensing events > 1 ED visit with asthma as the principal diagnosis > 1 hospital admission with asthma as the principal diagnosis 4 ambulatory visits with asthma and > 2 asthma medication dispensing events One or two year
8 Relationship of HEDIS Persistent Asthma to Survey Persistent Asthma 2,895 HEDIS patients in 2006 completed survey in fall 2007 Survey-defined persistent asthma Daytime and nighttime symptoms Rescue therapy Activity limitation Regular controller therapy Exacerbations (> 1 requiring oral CS in past 12 months) Schatz, et al. Am J Manag Care 2010; 16: e281
9 Relationship of HEDIS to Survey Persistent Asthma (PA) 86.9 % of patients reported survey PA Follow-up survey 5 month later 95 % with 1 st survey PA had PA on 2 nd survey 54 % of those without 1 st survey PA had PA on 2 nd survey HEDIS requalification in % of patients with survey PA versus 22 % without survey PA
10 HEDIS Requalification and Subsequent Utilization 2007 HEDIS 2008 utilization requalification P Value* Yes (N=1,712) No (N=805) Hospitalization or ED visit Any oral corticosteroid Two or more oral corticosteroids 6.1 % 2.7 % % 28.0 % < % 10.9 % <.0001 SABA > % 8.9 % <.0001
11 Persistent Asthma: Conclusions HEDIS persistent asthma is generally consistent with survey-defined persistent asthma The two year HEDIS population is even more specific for persistent asthma and associated with increased utilization The two year HEDIS population is a valid population for outreach and quality of care assessment
12 Outline of Presentation Assessment of Severity Persistent asthma (HEDIS) Assessment of Impairment Short-acting β-agonist canister dispensings Assessment of Risk (Exacerbations) Prior exacerbations Short-acting β-agonist canister dispensings Assessment of Quality Care (HEDIS) Any controller measure Medication ratio measure Adherence measure
13 Beta Agonist Long Term Control Scale Beta agonist canister dispensings per year > 12 Two samples Random sample of adult 2250 KP patients (aged 18-56) with persistent asthma (1999) who completed survey in ,369 members of Southern California KP asthma database in 2002 and 2003 Schatz, et al. J Allergy Clin Immunol 2006;117:995
14 Relationship of Beta Agonist Scale to Patient-Reported Outcomes Mean Value to 2 3 to 6 7 to 12 > 12 0 AQLQ ATAQ AOMS Outcome All p <
15 Question Which of the following have been shown to predict an increased risk for asthma exacerbations in children and adults A. Dispensing > 6 short-acting beta agonist canisters in a 12 month period B. Dispensing 3 short-acting beta agonist canisters in a 12 month period C. Prior oral corticosteroid dispensing for asthma D. All of the above
16 Outline of Presentation Assessment of Severity Persistent asthma (HEDIS) Assessment of Impairment Short-acting β-agonist canister dispensings Assessment of Risk (Exacerbations) Prior exacerbations Short-acting β-agonist canister dispensings Assessment of Quality Care (HEDIS) Any controller measure Medication ratio measure Adherence measure
17 Outline of Presentation Assessment of Severity Persistent asthma (HEDIS) Assessment of Impairment Short-acting β-agonist canister dispensings Assessment of Risk (Exacerbations) Prior exacerbations Short-acting β-agonist canister dispensings Assessment of Quality Care (HEDIS) Any controller measure Medication ratio measure Adherence measure
18 Relationship of Beta Agonist Scale to Utilization Outcomes % Hosp/ED Outcome Steroids 0 to 2 3 to 6 7 to 12 > 12 All p < 0.001
19 Risk of More Than 6 Short-Acting Beta-agonist Canisters Per Year 93,604 patients aged US Health Plans Risk in following year Odds Ratios (95 % Confidence Intervals) ED/Urgent Care: 6.47 ( ) Hospitalization: 5.37 ( ) Oral corticosteroid: 2.89 ( ) Silver HS, et al. Am J Manag Care 2011; 17:19
20 Short-acting Beta-agonist (SABA) Dispensings and Exacerbations Commercial and Medicaid Databases Children aged 4-17 years Commercial: 41,753 Medicaid: 25,048 Adults aged 18 years Commercial: 59,684 Medicaid: 8,745 Assessment of SABA in 12 month period Exacerbation outcomes Stanford RH, et al. Ann Allergy Asthma Immunol 2012; 109:403
21 Prediction of Asthma Exacerbations Cohort Critical SABA use Exacerbation Odds Ratios (95 % Confidence Interval) Hospital/ED Visit Oral Corticosteroid Medicaid Children 3 in 12 months 1.80 ( ) 1.38 ( ) Commercial Children 3 in 12 months 2.23 ( ) 1.60 ( ) Medicaid Adults 2 in 3 months 1.84 ( ) 1.15 ( ) Commercial Adults 2 in 6 months 2.21 ( ) 1.45 ( )
22 Outline of Presentation Assessment of Severity Persistent asthma (HEDIS) Assessment of Impairment Short-acting β-agonist canister dispensings Assessment of Risk (Exacerbations) Prior exacerbations Short-acting β-agonist canister dispensings Assessment of Quality Care (HEDIS) Any controller measure Medication ratio measure Adherence measure
23 Question Which of the following HEDIS measures have been shown to be related to improved asthma outcomes, including patient-reported outcomes A. Asthma medication ratio measure B. Asthma adherence measure C. Any controller measure D. None of the above
24 Outline of Presentation Assessment of Severity Persistent asthma (HEDIS) Assessment of Impairment Short-acting β-agonist canister dispensings Assessment of Risk (Exacerbations) Prior exacerbations Short-acting β-agonist canister dispensings Assessment of Quality Care (HEDIS) Any controller measure Medication ratio measure Adherence measure
25 HEDIS Any Controller Numerator Any Asthma Controller Dispensing The following medications are considered valid controller medications: Inhaled corticosteroids Inhaled cromolyn and nedocromil Oral leukotriene modifier and theophylline medications Excludes long-acting beta agonists
26 Any Controller Use Is Associated With Increased Risk in HEDIS Patients 49,637 patients with HEDIS-defined persistent asthma in health plans in 3 regions Controller use in year 2000 Outcome: Asthma-related ED visit or hospitalization (ED/Hosp) in 6 months % ED/ Hosp following first medication Controller No Controller Berger, et al. Ann Allergy Asthma Immunol 2004; 93:538
27 Outline of Presentation Assessment of Severity Persistent asthma (HEDIS) Assessment of Impairment Short-acting β-agonist canister dispensings Assessment of Risk (Exacerbations) Prior exacerbations Short-acting β-agonist canister dispensings Assessment of Quality Care (HEDIS) Any controller measure Medication ratio measure Adherence measure
28 Asthma Medication Ratio Controllers/(Controllers + Short-acting Beta Agonists) Number of canisters or canister equivalents (30 day supplies of oral controllers) Ranges from 0 (no Controllers) to 1.0 (no Short-acting Beta Agonists) 0.5 appears to be the optimal cut-off (in relationship to improved outcomes)
29 Relationship of Medication Ratio to Acute Episodes 38,433 Southern California Kaiser Permanente patients with persistent asthma Medication ratio determined in 2002 Acute episodes (one or more asthma emergency department visits or hospitalizations) determined in 2003 Schatz, et al. Chest 2005; 128:1068
30 Relationship of Medication Ratio to Acute Episodes % ED or Hospital < 0.5 > 0.5 Medication Ratio P <
31 Relation of Medication Ratio to Patient-Reported Outcomes Random sample of 2250 adult patients (aged 18-56) with persistent asthma (1999) Northern California, Southern California, and Northwest Kaiser Permanente Survey completed in Fall, 2000 Survey included quality of life (AQLQ), control (ATAQ) and symptom severity (AOMS) Medication ratio from year 2000 computerized pharmacy records Schatz, et al. Chest 2006; 130:43
32 Relationship of Ratio > 0.5 to Poor Symptom Control % AQLQ < 3.9 ATAQ > 1 AOMS > 3 Ratio < 0.5 Ratio > 0.5 Patient-Reported Outcome Tool All p <
33 Medicaid Population 90,909 Medicaid patients aged 5-56 with persistent asthma in California and New York Reduction of risk of exacerbation in follow-up year in patients with ratio 0.5 Aged 5-56 Aged 5-19 Aged Aged Increased risk of exacerbations with HEDIS any controller measure in all age groups Yong, et al. J Allergy Clin Immunol 2009; 124:961
34 Predictors of High Medication Ratio Higher controller medication possession ratio (adherence) Lower SABA dispensings Specialty care Combination ICS-LABA therapy Leukotriene receptor antagonist controller Broder, et al. Am J Manag Care 2010; 16:170
35 Outline of Presentation Assessment of Severity Persistent asthma (HEDIS) Assessment of Impairment Short-acting β-agonist canister dispensings Assessment of Risk (Exacerbations) Prior exacerbations Short-acting β-agonist canister dispensings Assessment of Quality Care (HEDIS) Any controller measure Medication ratio measure Adherence measure
36 New HEDIS Adherence Measure HEDIS two year persistent asthma denominator Two Rates The percentage of members who remained on an asthma controller medication for at least 50% of their treatment period The percentage of members who remained on an asthma controller medication for at least 75% of their treatment period
37 New HEDIS Adherence Measure: Concerns Measuring adherence to inhaled medications from pharmacy data is methodologically challenging Variable accuracy of days supply field Varying MD directions and patient use Varying number of puffs per canister Relationship of this measure to actual medication adherence is uncertain Relationship of this measure to improved outcomes has not been tested
38 HEDIS Administrative Data Asthma Quality Measures: Conclusions The any controller measure is not related to improved asthma outcomes The medication ratio measure is related to improved asthma outcomes (impairment and risk) within health plans The relationship of the new adherence measure to asthma outcomes is unknown
39 Conclusion: Potential Patients for Intervention Persistent asthma and no controllers Patients with prior exacerbations Excess short-acting beta agonist canister dispensings > 6 in 12 months Consider 3 in 12 months in children Consider 2 in 6 months in adults Medication ratio < 0.5 in patients with persistent asthma
Asthma is a common chronic medical condition that is associated
Relationship of Asthma Control to Asthma Exacerbations Using Surrogate Markers Within a Managed Care Database Michael Schatz, MD, MS; Robert S. Zeiger, MD, PhD; Su-Jau T. Yang, PhD; Wansu Chen, MS; William
Improving asthma outcomes in large populations
Current perspectives Improving asthma outcomes in large populations Michael Schatz, MD, MS, and Robert S. Zeiger, MD, PhD San Diego, Calif This article summarizes our experience using administrative, survey,
ASSOCIATION OF ASTHMA CONTROL WITH HEALTH CARE UTILIZATION A PROSPECTIVE EVALUATION
Online Supplement for: ASSOCIATION OF ASTHMA CONTROL WITH HEALTH CARE UTILIZATION A PROSPECTIVE EVALUATION METHODS Population The Northwest Region of Kaiser Permanente (KPNW) is a large, federally qualified,
Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma
Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma Pharmacoepidemiology Unit July 10, 2014 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca
Optum Research Database Proportion of asthma patients with prescription fills for rescue and controller medications by year,
ASTHMA CHART 1 Optum Research Database Proportion of asthma patients with prescription fills for rescue and controller medications by year, 215-216 7 6 5 4 3 2 1 1 Controller medication 1 Rescue medication
Adherence to asthma controller medication regimens
Respiratory Medicine (2005) 99, 1263 1267 Adherence to asthma controller medication regimens D.A. Stempel a,, S.W. Stoloff b, J.R. Carranza Rosenzweig c, R.H. Stanford c, K.L. Ryskina d, A.P. Legorreta
Asthma represents a significant burden to the healthcare system.
n clinical n Predicting Asthma Outcomes in Commercially Insured and Medicaid Populations Richard H. Stanford, PharmD, MS; Manan B. Shah, PharmD, PhD; Anna O. D Souza, BPharm, PhD; and Michael Schatz, MD,
Learning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
Effects on Resource Utilization of Adding Salmeterol in Combination or Separately to Inhaled Corticosteroids
RESEARCH Effects on Resource Utilization of Adding Salmeterol in Combination or Separately to Inhaled Corticosteroids JAMES CHAN, PharmD, PhD; RITA L. HUI, PharmD, MS; and MICHELE M. SPENCE, PhD ABSTRACT
Asthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
2014 Physician Quality Reporting System Data Collection Form: Asthma (for patients aged 5-64)
2014 Physician Quality Reporting System Data Collection Form: Asthma (for patients aged 5-64) Physician Name: Patient Name: Last First MI Date of Birth: / / mm dd yyyy Gender: M F Patient Insured - Traditional
Improving the Management of Asthma to Improve Patient Adherence and Outcomes
Improving the Management of Asthma to Improve Patient Adherence and Outcomes Robert Sussman, MD Atlantic Health System Overlook Medical Center Asthma Remains a Serious Health Risk in the US Every day in
The Safety of Asthma and Allergy Medications in Pregnancy: New Horizons
The Safety of Asthma and Allergy Medications in Pregnancy: New Horizons Jennifer Namazy, MD Division of Allergy Scripps Clinic, San Diego Michael Schatz, MD, MS Department of Allergy Kaiser Permanente,
Asthma in Pregnancy. Michael Schatz, MD, MS Department of Allergy Kaiser Permanente Medical Center San Diego, CA. Introduction
Asthma in Pregnancy Michael Schatz, MD, MS Department of Allergy Kaiser Permanente Medical Center San Diego, CA Introduction Asthma is the most common potentially serious medical problem to complicate
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016
Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which
II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
Disclosure Statement. Epidemiological Data
EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov
Asthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
Methacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges
Methacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges AAAAI San Antonio Tx February 2013 Catherine Lemière MD, MSc Hôpital du
In 2002, it was reported that 72 of 1000
REPORTS Aligning Patient Care and Asthma Treatment Guidelines Eric Cannon, PharmD Abstract This article describes how the National Asthma Education and Prevention Program Guidelines for the Diagnosis and
Adult asthma management: focus on control
Adult asthma management: focus on control Jennifer W. McCallister, MD Associate Professor Pulmonary, Allergy, Critical Care & Sleep Medicine The Ohio State University Wexner Medical Center Objectives Apply
Michael S. Blaiss, MD
Michael S. Blaiss, MD Clinical Professor of Pediatrics and Medicine Division of Clinical Immunology and Allergy University of Tennessee Health Science Center Memphis, Tennessee Speaker s Bureau: AstraZeneca,
2. Does the patient have chronic urticaria? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Xolair (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
Improving asthma outcomes though education
Improving asthma outcomes though education Segment 1 Clinical Aspects of Asthma and Long term Plan Primary Care and Asthma Most common chronic disease of childhood. Primary care providers are expected
CME/CE POSTTEST CME/CE QUESTIONS
CME/CE POSTTEST CME/CE QUESTIONS Controlling Asthma Severity: Identifying Unmet Needs and Optimizing Therapeutic Options There are no fees for participating in and receiving continuing medical education
«Impact of a pharmaceutical intervention to improve adherence of inhaled medication in asthma and COPD patients»
«Impact of a pharmaceutical intervention to improve adherence of inhaled medication in asthma and COPD patients» Baseline data from a randomized controlled trial 5 th Swiss Health Services Research Symposium,
Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.
Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr
The methodology behind GINA and EPR-3 medication recommendations: Stepwise treatment in asthma
The methodology behind GINA and EPR-3 medication recommendations: Stepwise treatment in asthma Maureen George PhD RN AE-C FAAN Columbia University mg3656@cumc.columbia.edu Faculty Disclosures Maureen George
Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION
Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION Asthma Management in Pregnancy Effects of asthma on pregnancy outcomes Effects of pregnancy on asthma control Management
The clinical quality measures as selected by the Clinical Management subcommittee for 2016 for the adult population are:
For 2016 the Clinical Integration Program is moving its clinical quality measures from the Verisk Healthcare Quality and Risk Measures to the National Committee for Quality Assurance HEDIS based measures.
The National Asthma Education and Prevention Program s
Long-Acting b-agonist Among Children and Adults With Asthma Elizabeth A. Wasilevich, PhD, MPH; Sarah J. Clark, MPH; Lisa M. Cohn, MS; and Kevin J. Dombkowski, DrPH Managed Care & Healthcare Communications,
Methods to Diagnose Adherence Status
Methods to Diagnose Adherence Status March 4, 2014 Andrew G Weinstein MD Associate Clinical Professor Pediatrics Jefferson Medical College President, Adherence Management Systems Disclosures President,
Management of wheeze in pre-school children. Prof Colin Robertson, Respiratory Medicine, Royal Children s Hospital, Melbourne
Management of wheeze in pre-school children Prof Colin Robertson, Respiratory Medicine, Royal Children s Hospital, Melbourne General Practitioner encounters for asthma Asthma in Australia, 2003 Emergency
Outcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom
Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom 2 BEYOND SYMPTOMS ADDRESSING FUTURE RISK IN ASTHMA South GP CME 2013,
Global Initiative for Asthma (GINA) What s new in GINA 2015?
Global Initiative for Asthma (GINA) What s new in GINA 2015? GINA Global Strategy for Asthma Management and Prevention What s new in GINA 2015 (1) Add-on tiotropium by soft-mist inhaler is a new other
Air Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.
Asthma Air Flow Limitation In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. True whether reversible, asthma and exercise-induced bronchospasm,
Disease Management. Measures At A Glance
s At A Glance Updated: 11/01/2018 URAC 2018 Page 1 of 7 Cross-Cutting Mandatory s (3) Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on
Detroit: The Current Status of the Asthma Burden
Detroit: The Current Status of the Asthma Burden Peter DeGuire, Binxin Cao, Lauren Wisnieski, Doug Strane, Robert Wahl, Sarah Lyon Callo, Erika Garcia, Michigan Department of Health and Human Services
Decramer 2014 a &b [21]
![Decramer 2014 a &b [21]](/thumbs/90/101390504.jpg "Decramer 2014 a &b [21]")
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
RESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma
Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
PATIENT-IMPACT SCORECARD
UNDERSTANDING THE GSC PATIENT-IMPACT SCORECARD What is the GSC Patient-Impact Scorecard? The GSC Patient-Impact Scorecard shows pharmacy performance scores for GSC patients during the period indicated.
Structural Equation Modeling of Health Literacy and Medication Adherence by Older Asthmatics
Structural Equation Modeling of Health Literacy and Medication Adherence by Older Asthmatics Alex Federman, MD, MPH Division of General Internal Medicine Icahn School of Medicine at Mount Sinai New York,
Asthma drug ratios and exacerbations: claims data from universal health coverage systems
ORIGINAL ARTICLE ASTHMA Asthma drug ratios and exacerbations: claims data from universal health coverage systems Laurent Laforest 1, Idlir Licaj 1, Gilles Devouassoux 2,Gérard Chatte 3, Jennifer Martin
Health care education, delivery, and quality
Relationships among quality of life, severity, and control measures in asthma: An evaluation using factor analysis Michael Schatz, MD, MS, a David Mosen, PhD, e Andrea J. Apter, MD, MSc, f Robert S. Zeiger,
Predicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa
Predicting, Preventing and Managing Asthma Exacerbations Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Asthma exacerbations Predicting exacerbation recognising
Presented by the California Academy of Family Physicians 2013/California Academy of Family Physicians
Family Medicine and Patient-Centered Asthma Care Presented by the California Academy of Family Physicians Faculty: Hobart Lee, MD Disclosures: Jeffrey Luther, MD, Program Director, Memorial Family Medicine
Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD
Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor
GSK Clinical Study Register
In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register. The
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
Provider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
Disease Management. Measures At A Glance
s At A Glance Updated: 11/2/2017 Page 1 of 7 Cross Cutting Mandatory s (4) Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual
Ethnic disparities in asthma treatment and outcomes in children aged under 15 years in New Zealand: analysis of national databases
Prim Care Respir J 2013; 22(3): 312-318 RESEARCH PAPER Ethnic disparities in asthma treatment and outcomes in children aged under 15 years in New Zealand: analysis of national databases Todd D Gillies
NG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
Evaluation of Asthma Management in Middle EAst North Africa Adult population
STUDY REPORT SUMMARY Evaluation of Asthma Management in Middle EAst North Africa Adult population Descriptive study on the management of asthma in an asthmatic Middle East Africa adult population Background/Rationale:
Improving Asthma Care: An Update for Managed Care
n posttest n Improving Asthma Care: An Update for Managed Care Physician Continuing Medical Education Accreditation Statement This activity has been planned and implemented in accordance with the Essential
TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department
TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN Dr Lại Lê Hưng Respiratory Department Literature review current through: Feb 2013. This topic last updated: Aug 14, 2012 INTRODUCTION Wheezing
Four of 10 patients with asthma suffer moderate REVIEW DUAL-CONTROLLER REGIMENS II: OBSERVATIONAL DATA. Michael S. Blaiss, MD ABSTRACT
DUAL-CONTROLLER REGIMENS II: OBSERVATIONAL DATA Michael S. Blaiss, MD ABSTRACT The differences between clinical trials and clinical practice often create difficulty for generalizing results of controlled
Title of Project: NHS Dumfries & Galloway Respiratory Bundle Asthma: Bronchodilator Overuse Review April 2015
Title of Project: NHS Dumfries & Galloway Respiratory Bundle Asthma: Bronchodilator Overuse Review April 2015 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate
Alberta Childhood Asthma Pathway for Primary Care
Asthma Diagnosis Box 1 Diagnosis: Based on symptom pattern, careful and thorough history of symptoms (wheeze, cough, night waking and activity limitations), and assessment of family history of asthma and
GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
BUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
Process quality measures and asthma exacerbations in the Medicaid population
Process quality measures and asthma exacerbations in the Medicaid population Pierre L. Yong, MD, MPH, a,b,c,d,e and Rachel M. Werner, MD, PhD a,d Philadelphia, Pa Background: Asthma quality assessment
Assessing Primary Care Physician s Beliefs and Attitudes of Asthma Exacerbation Treatment and Follow-Up
The Open Respiratory Medicine Journal, 2010, 4, 9-14 9 Assessing Primary Care Physician s Beliefs and Attitudes of Asthma Exacerbation Treatment and Follow-Up Open Access William Lincourt *,1, Richard
Estimated date of first patient enrolled Q III/IV Estimated date of last patient completed Q3 2015
PROTOCOL SYNOPSIS A 26 week, randomized, double-blind, parallel-group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma-related events during treatment with
Children First Medical Group Physicians. Steven Yedlin, MD, Chief Medical Officer Medical Director. DATE: January 3, 2008
TO: FROM: Children First Medical Group Physicians Steven Yedlin, MD, Chief Medical Officer Medical Director DATE: January 3, 2008 RE: Asthma Clinical Practice Guideline Revision Children First Medical
Asthma ASTHMA. Current Strategies for Asthma and COPD
Current Strategies for Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor of Medicine Chair, Department of Medicine University of California San Francisco (UCSF) San Francisco,
Exercise-Induced Bronchospasm. Michael A Lucia, MD, FCCP Asst Clinical Professor, UNR School of Medicine Sierra Pulmonary & Sleep Institute
Exercise-Induced Bronchospasm Michael A Lucia, MD, FCCP Asst Clinical Professor, UNR School of Medicine Sierra Pulmonary & Sleep Institute EIB Episodic bronchoconstriction with exercise May be an exacerbation
#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
Improving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
Asthma in the Athlete
Asthma in the Athlete Jorge E. Gomez, MD Associate Professor Texas Children s Hospital Baylor College of Medicine Assist Team Physician UH Understand how we diagnose asthma Objectives Be familiar with
Peak Expiratory Flow Rate (PEFR) for ED Management of Acute Asthma Exacerbation
Peak Expiratory Flow Rate (PEFR) for ED Management of Acute Asthma Exacerbation PI: Brian Driver, MD Checklist Reviewed Inclusion and Exclusion Criteria Confirm pertinent exclusion criteria with PMP Engage
James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD
Therapeutic Effect of Zafirlukast as Monotherapy in Steroid-Naive Patients With Severe Persistent Asthma* James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren,
Step up if needed (first, check adherence, environmental control and comorbid conditions) Patients ASSESS CONTROL. Step down if possible
12/9/212 Pharmacogenomics Treating the Individual Asthma Patient Elliot Israel, M.D. Professor of Medicine Harvard Medical School Brigham & Women s Hospital Partners Asthma Center Too much of a good thing?
** REGULATORY ALERT **
Complete Summary GUIDELINE TITLE Attaining optimal asthma control: a practice parameter. BIBLIOGRAPHIC SOURCE(S) Joint Task Force on Practice Parameters. Attaining optimal asthma control: a practice parameter.
Asthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
Asthma for Primary Care: Assessment, Control, and Long-Term Management
Asthma for Primary Care: Assessment, Control, and Long-Term Management Learning Objectives After participating in this educational activity, participants should be better able to: 1. Choose the optimal
Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007
Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007 TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS Selecting Initial Therapy
Adult Asthma Clinical Practice Guideline Summary
Adult Asthma Clinical Practice Guideline Summary The following evidence-based guideline was developed to assist Primary Care physicians and other clinicians in the management of asthma in adults. It was
New TLD Indication: Asthma RELIEF-1 Study. Nick ten Hacken, MD Study Co-Principal Investigator
New TLD Indication: Asthma RELIEF-1 Study Nick ten Hacken, MD Study Co-Principal Investigator The Burden of Asthma WW Adult Asthma Prevalence 230.5 Million Mild/Intermittent 161.9 Million (70%) Moderate
Asthma and Adherence to Inhaled Corticosteroids: Current Status and Future Perspectives
Asthma and Adherence to Inhaled Corticosteroids: Current Status and Future Perspectives Camilla Boslev Bårnes MD and Charlotte Suppli Ulrik MD DMSc Introduction Methods Review of the Literature Adherence
Policy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists
Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Policy Evaluation: Step Therapy Prior
Using an Asthma Control Questionnaire and Administrative Data To Predict Health-Care Utilization*
Original Research ASTHMA Using an Asthma Control Questionnaire and Administrative Data To Predict Health-Care Utilization* Dawn Peters, PhD; Chuhe Chen, PhD; Leona E. Markson, ScD; Felicia C. Allen-Ramey,
COPD COPD. Update on COPD and Asthma
Update on COPD and Asthma Talmadge E. King, Jr., M.D. Krevins Distinguished Professor of Medicine Chair, Department of Medicine University of California San Francisco (UCSF) San Francisco, CA COPD COPD
BUKSTEIN, MD; ALLAN LUSKIN, MD; SHIVA G. SAJJAN,
RESEARCH Administrative Claims Analysis of Asthma-Related Health Care Utilization for Patients Who Received Inhaled Corticosteroids With Either Montelukast or Salmeterol as Combination Therapy FELICIA
December 7, 2010 Future Use of Biologics in Allergy and Asthma
December 7, 2010 Future Use of Biologics in Allergy and Asthma Lanny J. Rosenwasser, M.D. Dee Lyons/Missouri Endowed Chair in Immunology Research Professor of Pediatrics Allergy-Immunology Division Childrens
Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
Original Article. ARTICLE INFO Article history: Received 9 September 2017 Received in revised form 19 November 2017 Accepted 20 November 2017
Original Article Pharm Sci Asia 2018; 45 (1), 13-21 DOI : 10.29090/psa.2018.01.013 Investigation on medication use and factors associated with levels of asthma control among asthmatic outpatients at University
Asthma: Chronic Management. Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015
Asthma: Chronic Management Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015 Global Strategy for Asthma Management and Prevention Evidence-based Implementation
Clinical Quality Measures Summary of Upcoming Enhancements
Upcoming coding enhancements will impact the logic behind the clinical quality indicators applicable to your practice specialty. Please refer to this grid for a summary of the coding enhancements and some
The prevalence and severity of chronic asthma have
An Economic Analysis of Alternative Step-Up Therapies in Asthma Patients Receiving Inhaled Daniel A. Ollendorf, MPH, Alyssa S. Pozniak, BA, Brian W. Bowers, PharmD, Gerry Oster PhD ABSTRACT We analyzed
Step 2: Identify patients who were dispensed at least two consecutive fills for any asthma medication (Table ACT-A: Asthma
NATIONAL QUALITY FORUM Measure Submission and Evaluation Worksheet 5.0 This form contains the information submitted by measure developers/stewards, organized according to NQF s measure evaluation criteria
Asthma 2015: Establishing and Maintaining Control
Asthma 2015: Establishing and Maintaining Control Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) Karen Meyerson, MSN, APRN, NP-C, AE-C June 16, 2015 Asthma Prevalence Approx. 26